Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.58 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.49 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27595258 | 0.88 | ANPEP (0.54) | ANPEPENPEPMRGPRX4CA12CA1 | |
| SCHEMBL6756207 | 0.88 | ANPEP (0.58) | ANPEPENPEPMRGPRX4CA12CA1 | |
| SCHEMBL19529333 | 0.84 | ANPEP (0.54) | ANPEPENPEPMRGPRX4CA12CA1 | |
| SCHEMBL10653107 | 0.84 | ANPEP (0.54) | ANPEPENPEPMRGPRX4CA12CA1 | |
| SCHEMBL28803735 | 0.84 | PTGS1 (0.46) | ANPEPENPEPMRGPRX4MAPTPTGS1 | |
| SCHEMBL30354039 | 0.83 | ANPEP (0.58) | ANPEPENPEPMRGPRX4CA12CA1 | |
| SCHEMBL30444032 | 0.83 | RXRA (0.66) | ANPEPENPEPMRGPRX4CA12CA1 | |
| SCHEMBL371525 | 0.83 | ANPEP (0.58) | ANPEPENPEPMRGPRX4CA12CA1 | |
| SCHEMBL105264 | 0.83 | RXRA (0.66) | ANPEPENPEPMRGPRX4CA12CA1 | |
| SCHEMBL2957369 | 0.83 | ANPEP (0.61) | ANPEPENPEPCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| CN-118159537-A | 6-Aza-quinoline derivatives and related uses | 黑钻治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118026939-A | Preparation method and application of fluorine-containing alkyl sulfonyl benzimidazole compound | 广东方中高新材料有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024038128-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| CN-1898244-A | Triazole derivatives as vasopressin antagonists | PFIZER (US) | 2007-01-17 | — | — | CN | disclosed |
| EP-1701959-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| US-20050282882-A1 | Diamines as modulators of chemokine receptor activity | CARTER PERCY | 2005-12-22 | — | — | US | disclosed |
| US-6974836-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
| EP-1351924-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Pharma Company (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-27 | — | — | US | disclosed |
| WO-2002050019-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | ANPEP 4537/4885ENPEP 3463/4885MRGPRX4 102/4885 |
| US-20050282882-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | ANPEP 711/4885ENPEP 776/4885MRGPRX4 81/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | ANPEP 140/4885ENPEP 96/4885MRGPRX4 3314/4885 |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | TOP2A, TOP2B, UGT2B7 | ANPEP 3924/4885ENPEP 3699/4885MRGPRX4 1366/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ANPEP 1467/4885ENPEP 2691/4885MRGPRX4 1410/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | ANPEP 3005/4885ENPEP 3526/4885MRGPRX4 1607/4885 |
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | ANPEP 2857/4885ENPEP 2709/4885MRGPRX4 330/4885 |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | ANPEP 779/4885ENPEP 870/4885MRGPRX4 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.